Biochemical and pharmacological properties of symmetrical 2,5-disubstituted 1,3,4-oxadiazoles.
D000806:Angiotensin-Converting Enzyme Inhibitors; D000818:Animals; D000927:Anticonvulsants / Q000138:chemical synthesis; D002800:Cholinesterase Inhibitors / Q000138:chemical synthesis; D066298:In Vitro Techniques; D007928:Lethal Dose 50; D051379:Mice; D008996:Monoamine Oxidase Inhibitors / Q000138:chemical synthesis*; D010069:Oxadiazoles / Q000138:chemical synthesis* / Q000494:pharmacology / Q000633:toxicity; D051381:Rats; D012110:Reserpine / Q000037:antagonists & inhibitors; D013329:Structure-Activity Relationship
D000806:Angiotensin-Converting Enzyme Inhibitors; D000927:Anticonvulsants; D002800:Cholinesterase Inhibitors; D008996:Monoamine Oxidase Inhibitors; D010069:Oxadiazoles; D012110:Reserpine